Corporation evaluating next steps following vote outcome
OTTAWA, ON, Aug. 1, 2025 /CNW/ - The Canada Industrial Relations Board (CIRB) has informed Canada Post that a...
LOS ANGELES, Aug. 1, 2025 /PRNewswire/ -- Insurance Commissioner Ricardo Lara is breaking his promise to Californians by guaranteeing rate hikes without guaranteeing more coverage,...
NEWARK, N.J., Aug. 1, 2025 /PRNewswire/ -- Public Service Enterprise Group (NYSE: PEG) today announced that it has received notice of an unsolicited mini-tender offer by...
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The Boards of Trustees/Directors of the PIMCO closed-end funds below (each, a “Fund” and, collectively, the “Funds”) have declared a monthly distribution for each Fund’s common shares as summarized below.
VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
THOUSAND OAKS, Calif., Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for...
The Supply Veins Co-Founder and CEO is a PenFed Foundation for Military Heroes Veteran Entrepreneur Program Alumnus
Multimedia: VIDEO LINK
MIAMI, Aug. 1, 2025 /PRNewswire/ -- Autoket,...
Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.
BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovations to improve health and wellness...
Wenzhou, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Erayak Power Solution Group Inc. (NASDAQ: RAYA) ("Erayak" or the "Company"), a leading manufacturer, designer, and exporter of high-quality products in the power supply industry, today announced the closing of its previously announced registered direct offering with certain institutional investors for the sale and purchase of an aggregate of 107,692,307 of the Company’s Class A ordinary shares, par value $0.0001 per share (the “Shares”) (or Class A ordinary share equivalents in lieu thereof) in a registered direct offering at a purchase price of $0.065 per share. The purchase price for the pre-funded warrants was $0.065 to the purchase price for Shares, less the exercise price of $0.0001 per share.
Premium Materials. Timeless Western Sophistication.
FORT WORTH, Texas, Aug. 1, 2025 /PRNewswire/ -- Tony Lama, a name synonymous with fine craftsmanship and Western tradition, has...